FDA panel backs Pfizer drug for kidney cancer
(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.
Dec 7, 2011
0
0